Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia

Background The cardiotoxic effect of anthracyclines has been well described for moderate to high cumulative doses (>350 mg/m2). However, the question of whether sub‐clinical signs of cardiomyopathy may develop and progress over time in children receiving doses of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2010-03, Vol.54 (3), p.444-448
Hauptverfasser:	Rathe, Mathias, Carlsen, Niels Lauritz Torp, Oxhøj, Henrik, Nielsen, Gunner
Format:	Artikel
Sprache:	eng
Schlagworte:	acute lymphoblastic leukemia Adolescent anthracyclines Anthracyclines - administration & dosage Anthracyclines - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Cardiomyopathies - chemically induced Cardiomyopathies - diagnostic imaging cardiotoxicity Child Child, Preschool children Cohort Studies Dose-Response Relationship, Drug Echocardiography Female Follow-Up Studies Humans Infant Male Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Sex Factors Stroke Volume - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background The cardiotoxic effect of anthracyclines has been well described for moderate to high cumulative doses (>350 mg/m2). However, the question of whether sub‐clinical signs of cardiomyopathy may develop and progress over time in children receiving doses of
ISSN:	1545-5009 1545-5017
DOI:	10.1002/pbc.22302